Tempest Therapeutics Corp (TPST): Expected earnings per share growth for next year
Despite the slow pace of clinical trials, where physicians remain indispensable, AI is accelerating molecule modeling for Tempest Therapeutics (TPST). The trend in consensus EPS forecasts for the coming year visualizes these complexities, and 68.40 becomes the new value for this metric. The solution is a proprietary cancer metabolism modulation platform, while steady demand for biotechnology provides the company with defensive qualities against macroeconomic downturns.
tempesttx.com (TPST) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization information:
- debt burden and liquidity indicators:
Debt to Equity Tempest Therapeutics|TPST - Long-Term Liabilities to Equity|Short-Term Debt to Capital Tempest Therapeutics, Inc.|TPST - Company Cumulative Debt|Debt to Book Capitalization Ratio Tempest Therapeutics|TPST - Long-Term Debt Volume|Company Current Liabilities Tempest Therapeutics|Quick Liquidity Indicator tempesttx.com
- earnings and valuation multiples information:
TPST - Final Profit|Future Profit Tempest Therapeutics|TPST - Market Price to Net Income Ratio|Forward P/E Multiple Tempest Therapeutics|TPST - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Tempest Therapeutics|TPST - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Tempest Therapeutics|TPST - Earnings per share for the trailing year|Quarterly EPS earnings growth tempesttx.com|TPST - Earnings growth in current year|Net earnings per share growth forecast for next year Tempest Therapeutics
Fundamental company analysis:TPST, Tempest Tx
For the biopharmaceutical sector, earnings forecasts serve as a leading indicator of asset value during clinical trials. By analyzing the expected EPS change for the coming year, an investor can observe the aggregated trend of expert revisions to earnings per share. In the case of Tempest Therapeutics (TPST), this metric reflects the binary risk associated with the success of its oncology pipeline, where any shifts in the curve signal a reassessment of the probability of drug commercialization.
Competitor analysis
ONC (BeiGene Corp) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Corp HALO|Expected earnings per share growth for next year RVMD (Revolution Medicines)|Projected earnings per share increase next year AAPG|Earnings growth forecast for next year CGON (CG Oncology)|UroGen Pharma Ltd (URGN) - Expected net earnings per share growth next year|BCAX - Net earnings per share growth forecast for next year|Personalis Genomics (PSNL) - Expected earnings per share growth for next year|Erasca, Inc. (ERAS) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year DCTH (delcath.com)|YMAB (Y-mAbs Therapeutics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year Aura Biosciences Inc AURA|Net earnings per share growth forecast for next year Candel Therapeutics (CADL)|Consensus forecast of earnings per share growth for next year Accuray, Inc.|SELLAS Life Sciences Group - Expected earnings per share growth for next year|Projected earnings per share increase next year ACTU (actuatetherapeutics.com)|CTOR: Expected earnings per share growth for next year|Expected earnings per share trend next year HURA (TuHURA Biosciences, Inc.)|TARA (Protara) - Expected earnings per share growth for next year|FATE: Projected earnings per share increase next year|WHWK (Aadi Bioscience, Inc.) - Earnings growth forecast for next year|TCRX: Expected earnings per share trend next year|Earnings growth forecast for next year CSBR|XBIT - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year CEL-SCI CVM|Expected earnings per share trend next year OSTX|Radiopharm Theranostics Limited - Earnings growth forecast for next year|ARTV - Earnings growth forecast for next year|adlainortye.com (ANL) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year VERU (Veru Inc)|XLO (Xilio Therapeutics Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Enochian BioSciences RENB|Expected earnings per share growth for next year MURA (Mural Oncology plc)|Earnings growth forecast for next year kairospharma.com (KAPA)|OnKure Therapeutics - Expected earnings per share growth for next year|Projected earnings per share increase next year GDTC (CytoMed Therapeutics Ltd)|Curis Corp - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Apollomics, Inc. APLM|THAR: Earnings growth forecast for next year|Expected earnings per share growth for next year Advanced Biomed|Net earnings per share growth forecast for next year Genprex|Calidi Bio (CLDI) - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year SBFM (Sunshine Biopharma, Inc.)|Projected earnings per share increase next year XBIO|Net earnings per share growth forecast for next year Salarius Pharmaceuticals SLRX|PPBT (purple-biotech.com) - Net earnings per share change forecast for next year|AONC - Net earnings per share growth forecast for next year|Consensus forecast of earnings per share growth for next year BeiGene Ltd. BGNE|CKPT (Checkpoint Therapeutics, Inc) - Expected earnings per share growth for next year|ELEV: Projected earnings per share increase next year|ICAD (iCAD Inc.) - Earnings growth forecast for next year|Expected earnings per share growth for next year Ikena (IKNA)|Earnings growth forecast for next year NTBL|Earnings growth forecast for next year viracta.com (VIRX)|Net earnings per share growth forecast for next year MorphoSys Corp MOR|NAYA: Projected earnings per share growth rate for next year|Ascentage Pharma Group - Earnings growth forecast for next year
